Pathological Gambling Associated with Dopamine Agonist Therapy in Parkinson's
Neurol 61:422-423, Driver-Dunckley,E.,et al, 2003
Paraneoplastic Syndromes Involving the Nervous System
NEJM 349:1543-1554, Darnell,R.B. &Posner,J.B., 2003
Orthostatic Hypotension in De Novo Parkinson Disease
Arch Neurol 60:1400-1404, Bonuccelli,U.,et al, 2003
Disappearance of Resting Tremor After "Stereotaxic" Thalamic Stroke
Neurol 61:1014-1015, Probst-Cousin,S.,et al, 2003
Constipation in Neurological Diseases
JNNP 74:13-19, Winge,K.,et al, 2003
Clinicopath Conf., Chronic Inflammatory Demyelinating Polyneuropathy
NEJM 348:735-743, Case 6-2003, 2003
Reversal of Parkinsonism Following Liver Transplantation
Neurol 60:519, Shulman,L.J.,et al, 2003
Slowing Parkinson's Disease Progression
Neurol 60:381-389, Ahlskog,J.E., 2003
Initial Agonist Treatment of Parkinson Disease
Neurol 60:390-394, Albin,R.L. &Frey,K.A., 2003
[123I]b-CIT SPECT is a Useful Method for Monitoring Dopaminergic Degeneration in Early Stage Parkinson's Disease
JNNP 74:294-298,287, Winogrodzka,A.,et al, 2003
Vestibular Neuritis
NEJM 348:1027-1032, Baloh,R.W., 2003
Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003
Neuronal Loss Is Greater in the Locus Coeruleus Than Nucleus Basalis and Substantia Nigra in Alzheimer and Parkinson Diseases
Arch Neurol 60:337-341, 320, Zarow,C.,et al, 2003
Clinical Features and Natural Histry of Progressive Supranuclear Palsy, A Clinical Cohort Study
Neurol 60:910-916, Nath,W.,et al, 2003
Diffusion-Weighted Imaging Discriminates Progressive Supranuclear Palsy from PD, But Not From the Parkinson Variant of Multiple System Atrophy
Neurol 60:922-927, Seppi,K.,et al, 2003
Predictors of Nursing Home Placement in Huntington Disease
Neurol 60:998-1001, Wheelock,V.L.,et al, 2003
Stem Cells and Neurological Disease
JNNP 74:553-557, Barker,R.A.,et al, 2003
Randomized Trial of Pallidotomy Versus Medical Therapy for Parkinson's Disease
Ann Neurol 53:558-569, Vitek,J.L.,et al, 2003
Weight Loss in Parkinson's Disease
Ann Neurol 53:676-679, Chen,H.,et al, 2003
Parkinson Disease With Old-Age Onset
Arch Neurol 60:529-533, Diederich,N.J.,et al, 2003
Identifying the Pattern of Olfactory Deficits in Parkinson Disease Using the Brief Smell Identification Test
Arch Neurol 60:545-549, Double,K.L.,et al, 2003
Cerebellar Ataxia and Coenzyme Q10 Deficiency
Neurol 60:1206-1208, Lamperti,C.,et al, 2003
Alzheimer's Disease and Parkinson's Disease
NEJM 348:1356-1364, Nussbaum,R.L. &Ellis,C.E., 2003
Prevalence of Antigliadin Antibodies in Ataxia Patients
Neurol 60:1674-1675,1566, Abele,M.,et al, 2003
Neurologic Manifestations of Vitamin B12 Deficiency
NEJM 348:2208, Scherer,K., 2003
Intakes of Vitamins E and C, Carotenoids, Vitamin Supplements, and PD Risk
Neurol 59:1161-1169, Zhang,S.M.,et al, 2002
T2-weighted MRI Differentiates Multiple System Atrophy from Parkinson's Disease
Neurol 59;1265-1267, Kraft,E.,et al, 2002
Familial Dementia With Lewy Bodies
Arch Neurol 59:1622-1630, Tsuang,D.W.,et al, 2002
Mitochondrial Therapy for Parkinson Disease
Arch Neurol 59:1523, Rosenberg,R.N., 2002
Nonmotor Fluctuations in Parkinson's Disease
Neurol 59:408-413, Witjas,T.,et al, 2002
Clinical Features and ATTCT Repeat Expansion in Spinocerebellar Ataxia Type 10
Arch Neurol 59:1285-1290, Grewal,R.P.,et al, 2002
A Meta-Analysis of Coffee Drinking, Cigarette Smoking, and the Risk of Parkinson's Disease
Ann Neurol 52:276-284,261, Hernan,M.A.,et al, 2002
Clinicopath Conf, Neuronal Ceroid Lipofuscinosis, Late-Onset Infantile Subtype
NEJM 347:672-680, Case 27-2002, 2002
Clinicopath Conf., Cerebral Venous Thrombosis, Resulting in Hemorrhagic Infarction of the Posterior Left Temporal Lobe
NEJM 346:1651-1658, Case 16-2002, 2002
Donepezil for Cognitive Impairment in Parkinson's Disease: A Randomised Controlled Study
JNNP 72:708-712, Aarsland,D.,et al, 2002
Incidence and Prediction of Falls in Parkinson's Disease: A Prospecitve Multidisciplinary Study
JNNP 72:721-725, Wood,B.H.,et al, 2002
Therapies for Movement Disorders
Arch Neurol 59:699-702, Goetz,C.G &Hinson,V.K., 2002
Friedreich Ataxia
Arch Neurol 59:743-747, Lynch,D.R.,et al, 2002
Treatment Interventions for Parkinson's Disease: An Evidence Based Assessment
Lancet 359:1589-1598, Rascol,O.,et al, 2002
Gluten Sensitivity as a Neurological Illness
JNNP 72:560-563, Hadjivassiliou,M.,et al, 2002
Impact of Sustained Deprenyl (Selegiline) in Levodopa-Treated Parkinson's Disease: A Randomized Placebo-Controlled Extension of the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism Trial
Ann Nuerol 51:604-612, Shoulson,I.,et al, 2002
Opsoclonus-myoclonus Syndrome Following Epstein-Barr Virus Infection
Neurol 58:1131-1132, Verma,A. &Brozman,B., 2002
Cholinergic Vesicular Transporters in Progressive Supranuclesar Palsy
Neurol 58:1013-1018,997, Suzuki,M.,et al, 2002
Botulinum Toxin for Cricopharyngeal Dysfunction in Parkinson's Disease
NEJM 346:1174-1175, Restivo,D.A.,et al, 2002
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
Bilateral Subthalamic Nucleus Stimulation Improves Health-Related Quality of Life in PD
Neurol 59:1976-1978, Lagrange,E.,et al, 2002
How Valid is the Clinical Diagnosis of Parkinson's Disease in the Community?
JNNP 73:529-534, Scharg,A.,et al, 2002
Driving Safety in Parkinson's Disease
Neurol 59:1787-1788, Zesiewicz,T.A.,et al, 2002
Effect on Mood of Subthalamic DBS for Parkinson's Disease
Neurol 59:1427-1429, Berney,A.,et al, 2002
Mania Following Deep Brain Stimulation for Parkinson's Disease
Neurol 59:1421-1424, Kulisevsky,J.,et al, 2002